| |
Representative
publications |
1. Acquati F., Possati
L., Ferrante L., Campomenosi P., Talevi S., Bardelli S., Margiotta
C., Russo A., Bortoletto E., Rocchetti R., Calza R., Cinquetti R.,
Monti L., Salis S., Barbanti-Brodano G. and Taramelli R. (2005). Tumor
and metastasis suppression by the human RNASET2 gene. Int. J. Oncol.
26, 1159-1168.
2. Monti P., Iannone R., Campomenosi P., Ciribilli Y., Varadarajan
S., Shah D., Menichini P., Gold B. and Fronza G. (2004). Nucleotide
excision repair defect influences lethality and mutagenicity induced
by Me-lex, a sequence-selective N3-adenine methylating agent, in the
absence of base excision repair. Biochemistry 43, 5592-5599.
3. Monti P., Campomenosi P., Ciribilli Y., Iannone R., Aprile A.,
Inga A., Tada M., Menichini P., Abbondandolo A. and Fronza G. (2003).
Characterization of the p53 mutants ability to inhibit p73 transactivation
using a yeast-based functional assay. Oncogene 22, 5252-5260.
4. Monti P., Campomenosi P., Ciribilli Y., Iannone R., Inga A., Shah
D., Scott G., Burns P.A., Menichini P., Abbondandolo A., Gold B. and
Fronza G. (2002). Influences of base excision repair defects on the
lethality and mutagenicity induced by Me-lex, a sequence-selective
N3-Adenine methylating agent. J. Biol. Chem. 277, 28663-28668.
5. Monti P., Campomenosi P., Ciribilli Y., Iannone R., Inga A., Abbondandolo
A., Resnick M.A., Fronza G. (2002). Tumour p53 mutations exhibit promoter
selective dominance over wild type p53. Oncogene 21, 1641-1648.
6. Campomenosi P., Monti P., Aprile A., Abbondandolo A., Frebourg
T., Gold B., Crook T., Inga A., Resnick M.A., Iggo R. and Fronza G.
(2001). P53 mutants can often transactivate promoters containing a
p21 but not Bax or PIG3 responsive elements. Oncogene, 20, 3573-3579.
7. Maurici D., Monti P., Campomenosi P., North S., Frebourg T., Fronza
G. and Hainaut P. (2001). Amifostine (WR2721) restores transcriptional
activity of specific p53 mutant proteins in a yeast functional assay.
Oncogene, 20, 3533-3540.
8. Viaggi S., Gallerani E., Molina F., Nuesse M., Fronza G., Ottaggio
L., Campomenosi P., Abbondandolo A. and Menichini P. (2001). Partial
characterization of SUVi, a new mammalian gene induced by UV-C and
expressed during the S-phase of the cell cycle. Environ. Mol. Mutag.
37, 76-84
9. Fais F., Fronza G., Roncella S., Inga A., Campomenosi P., Cutrona
G., Pezzolo A., Fedeli F., Abbondandolo A., Chiorazzi N., Pistoia
V. and Ferrarini M. (2000). Analysis of the stepwise genetic changes
that occurred in an AIDS-related Burkitt’s lymphoma. Int. J.
Cancer, 88, 744-750.
10. Campomenosi P. and Hall P.A. (2000). Gadd45 mutations are uncommon
in human tumour cell lines. Cell Prolif. 33, 301-306.
11. Ottaggio L., Bozzo S., Moro F., Sparks A., Campomenosi P., Miele
M., Bonatti S., Fronza G., Lane D.P. and Abbondandolo A. (2000). Defective
nuclear localization of p53 protein in a Chinese hamster cell line
is associated with the formation of stable cytoplasmic protein multimers
in cells with gene amplification. Carcinogenesis 21, 1631-1638.
12. Fronza G., Inga A., Monti P., Scott G., Campomenosi P., Menichini
P., Ottaggio L., Viaggi S., Burns P.A., Gold B. and Abbondandolo A.
(2000). The yeast p53 functional assay: a new tool for molecular epidemiology.
Hopes and facts. Mutation Res. 462, 293-301.
13. Monti P., Inga A., Aprile A., Campomenosi P., Menichini P., Ottaggio
L., Viaggi S., Ghigliotti G., Abbondandolo A. and Fronza G. (2000).
P53 mutations experimentally induced by 8-methoxypsoralen plus UVA
(PUVA) differ from those found in human skin cancers in PUVA-treated
patients. Mutagenesis 15, 127-132.
14. Monti P., Inga A., Scott G., Aprile A., Campomenosi P., Menichini
P., Ottaggio L., Viaggi S., Abbondandolo A., Burns P.A. and Fronza
G. (1999). 5-Methylcytosine at HpaII sites in p53 is not hypermutable
after UVC irradiation. Mutation Res., 431, 93-103.
15. Ottaggio L., Moro F., Fronza G., Roncella S., Bozzo S., Campomenosi
P., Inga A., Ferrarini M. and Abbondandolo A. (1999). Derivative chromosome
17 in a case of Burkitt Lymphoma with 8;14 tranlocation. Cancer Genet
Cytogenet 110, 1-6.
16. Inga A., Chen F.X., Monti P., Aprile A., Campomenosi P., Menichini
P., Ottaggio L., Viaggi S., Abbondandolo A., Gold B. and Fronza G.
(1999). N-(2-Chloroethyl)-N-nitrosourea tethered to lexitropsin induces
minor groove lesions at the p53 cDNA that are more cytotoxic than
mutagenic. Cancer Res. 59, 689-695.
17. Campomenosi P., Assereto P., Bogliolo M., Fronza G., Abbondandolo
A., Capasso A., Bellomo P. F., Monaco R., Rapallo A., Sciutto A.,
Orecchia R., Geido E. and Giaretti W. (1998). p53 mutations and DNA
ploidy in colorectal adenocarcinomas. Analytical Cellular Pathology
17, 1-12.
18. Campomenosi P., Fronza G., Ottaggio L., Roncella S., Inga A.,
Bogliolo M., Monti P., Assereto P., Moro F., Cutrona F., Bozzo S.,
Chiorazzi N., Abbondandolo A. and Ferrarini M. (1997). Heterogeneous
p53 mutations in a Burkitt’s lymphoma from an AIDS patient with
monoclonal c-myc and vdj rearrangements. Int. J. Cancer 73, 816-821.
19. Bogliolo M., Fronza G., Campomenosi P., Assereto P., Izzotti A.,
Petrilli G.L., Abbondandolo A. and De Flora S. (1996). Cancer biomarkers
in human atherosclerotic lesions. Lack of mutations in K-ras codons
12 and 13. Chem. Biol. Interact. 102, 55-62.
20. Campomenosi P., Conio M., Bogliolo M., Urbini S., Aprile A., Assereto
P., Inga A., Aste H., Lapertosa G., Abbondandolo A. and Fronza G.
(1996). P53 is frequently mutated in Barrett’s Esophagus of
the intestinal type. Cancer Epidemiol. Biomarkers & Prevention
5, 559-565.
21. Campomenosi P., Ottaggio L., Moro F., Urbini S., Bogliolo M.,
Zunino A., Camoriano A., Inga A., Gentile S.L., Pellegata N., Bonassi
S., Bruzzone E., Iannone R., Pisani R., Menichini P., Ranzani G.N.,
Bonatti S., Abbondandolo A. and Fronza G. (1996). Study on aneuploidy
and p53 mutations in astrocytomas. Cancer Genet. Cytogenet. 88, 95-102.
22. Inga A., Iannone R., Campomenosi P., Molina F., Menichini P.,
Abbondandolo A. and Fronza G. (1995). Mutational fingerprint induced
by the antineoplastic drug Chloroethyl-Cyclohexyl-Nitroso-Urea in
mammalian cells. Cancer Res. 55, 4658-4663.
23. De Agostini F., Fronza G., Campomenosi P., Izzotti A., Petrilli
G.L., Abbondandolo A., De Flora S. (1994). Cancer biomarkers in human
atherosclerotic lesions. II. No evidence of p53 involvement. Cancer
Epidemiol. Biomarkers & Prevention 4, 111-115.
24. Fronza G., Madzak C., Campomenosi P., Inga A., Iannone R., Abbondandolo
A. and Sarasin A. (1994).Influence of DNA structure on the mutation
spectrum of 4-nitroquinoline 1-oxide damage single stranded shuttle
vector DNA transfected into Monkey cells. Mutation Res. 308, 117-125.
25. Menichini P., Inga A., Fronza G., Iannone R., Degan P., Campomenosi
P. and Abbondandolo A. (1994). Defective splicing induced by 4NQO
in the hamster hprt gene. Mutation Res. 323, 159-165.
26. Inga A., Iannone R., Campomenosi P., Fronza G., Abbondandolo A.
and Menichini P. (1994). Analysis of 4-nitroquinoline 1-oxide induced
mutations at the hprt locus in mammalian cells: possible involvement
of preferential DNA repair. Mutagenesis, 9, 67-72.
27. Campomenosi P., Iannone R.,. Inga A,. Menichini P,. Degan P.,
Abbondandolo A., Fronza G.. (1992). Multi-system approach to study
mutagenesis induced by chemical carcinogens. Bull. Italian Soc. Sperimental
Biol. 68, 699-705.
28. Iannone R., Campomenosi P., Madzak C., Inga A., Caocci F., Abbondandolo
A., Fronza G., Sarasin A.(1992) Single-stranded DNA vectors for analyzing
processing of DNA damage induced by 4-nitroquinoline 1-oxide in prokaryotes
and eukaryotes. Bull. Italian Soc. Sperimental Biol. 68, 619-624.
29. Inga A., Menichini P., Iannone R., Degan P., Campomenosi P., Fronza
G., Abbondandolo A. (1992). Study of 4-NQO induced mutations at the
HPRT locus in CHO cell lines. Possible influences of preferential
DNA-repair on the mutational spectrum. Bull. Italian Soc. Sperimental
Biol. 68, 581-586.
30. Fronza G., Campomenosi P., Iannone R. and Abbondandolo A. (1992).
The 4-nitroquinoline 1-oxide mutational spectrum in single stranded
DNA is characterized by guanine to pyrimidine transversions. Nucleic
Acids Res., 20, 1283-1287
|